Precision Medicine & Genomics
Precision Medicine & Genomics covers companies that use genomic, molecular and data-driven tools to personalize diagnosis, monitoring and treatment. Capital flows to this theme because lower sequencing costs, improved analytics and expanding clinical applications create revenue opportunities across diagnostics, labs and therapeutics.
8 of 15 stocks are in a Stage 2 uptrend.
Stocks in this theme
| Ticker | Price | 1M | 3M | 1Y | Stage | Trend | vs 52w high |
|---|---|---|---|---|---|---|---|
| CDNACareDx, Inc. | $65 | +29.7% | +122.2% | +337.4% | Stage 2 (extended) | 7/7 | 0% |
| GRALGRAIL, Inc. | $140.12 | +76.5% | +105.7% | +138.4% | Stage 3 | 5/7 | 0% |
| CAICaris Life Sciences, Inc. | $30.63 | +20.2% | +63.4% | +2.1% | Stage 1 | 6/7 | -7.04% |
| NTRANatera, Inc. | $413.31 | +28.4% | +49.6% | +153.4% | Stage 2 (extended) | 7/7 | -0.29% |
| ILMNIllumina, Inc. | $273.68 | +28.1% | +48.8% | +197.9% | Stage 2 (extended) | 7/7 | -0.08% |
| TEMTempus AI, Inc. | $81.9 | +29.9% | +33.0% | +4.2% | Stage 3 | 5/7 | -20.68% |
| ADPTAdaptive Biotechnologies Corp | $28.9 | +16.0% | +29.2% | +118.6% | Stage 2 (extended) | 7/7 | -2.27% |
| NEONeogenomics Inc | $18.36 | +2.5% | +22.6% | +131.5% | Stage 2 (extended) | 7/7 | -7.79% |
| DGXQuest Diagnostics Inc | $233.07 | -3.0% | +7.9% | +23.4% | Stage 2 (continuation) | 7/7 | -5.81% |
| GHGuardant Health, Inc. | $178.36 | +12.2% | +4.4% | +187.7% | Stage 2 (extended) | 7/7 | -2.59% |
| WGSGeneDx Holdings Corp. | $72.3 | -14.8% | +0.8% | -36.5% | Stage 3 | 3/7 | -56.84% |
| CRSPCRISPR Therapeutics AG | $55.32 | -2.9% | -0.5% | -13.3% | Stage 3 | 4/7 | -27.95% |
| LNTHLantheus Holdings, Inc. | $99.53 | -1.4% | -8.7% | +96.6% | Stage 1 | 7/7 | -10.28% |
| VCYTVeracyte, Inc. | $46.04 | +6.6% | -23.1% | +37.0% | Stage 2 (continuation) | 6/7 | -23.89% |
| BEAMBeam Therapeutics Inc. | $24.45 | -16.9% | -27.0% | +6.4% | Stage 1 | 1/7 | -35.52% |
Deep dive
Precision medicine and genomics means using DNA, RNA, protein and other molecular measurements to tailor clinical decisions for individuals. The theme includes diagnostic labs that run tests, instrument makers that generate molecular data, software and analytics firms that interpret results, and therapeutic developers that design targeted or gene-based treatments. The group of companies listed here spans those roles and aims to convert biological signals into clinical decisions or therapies.
Demand comes from several concrete trends. Falling costs and faster turnaround for sequencing and targeted assays make molecular testing accessible for more patients. Rising use of targeted cancer drugs, expanded prenatal screening, organ-transplant monitoring and growing awareness of rare genetic conditions push clinicians toward molecular answers. Advances in machine learning and cloud computing make it easier to integrate genomic data with clinical records, which supports new commercial services. Payer coverage and regulatory approvals shape how quickly tests move from research into routine care, and that reality attracts investment when approvals or reimbursement improve.
The value chain splits into distinct activities. Sample collection and high-volume clinical lab services come from national and specialty providers such as Quest Diagnostics (DGX) and Neogenomics (NEO). Sequencing instruments and core reagents are supplied by firms like Illumina (ILMN). Clinical genomics and interpretation services appear at companies such as Caris Life Sciences (CAI), GeneDx (WGS), Veracyte (VCYT), Natera (NTRA) and Guardant Health (GH), which offer tumor profiling, hereditary testing and liquid-biopsy assays. Data analytics and clinical decision platforms include Tempus AI (TEM) and Adaptive Biotechnologies (ADPT), which focus on bioinformatics and immune profiling. Therapeutic development and genome editing come from CRISPR Therapeutics (CRSP) and Beam Therapeutics (BEAM), while early-detection and population screening efforts appear at firms such as GRAIL (GRAL). Support services and specialty diagnostics, like transplant monitoring from CareDx (CDNA) and molecular imaging agents from Lantheus (LNTH), round out the chain.
Whether the theme continues to attract capital depends on practical factors. Clinical validation in peer-reviewed studies and demonstrated improvements in patient outcomes drive clinician adoption. Stable reimbursement policies and clear regulatory pathways enable scalable business models. Data scale, quality and integration with electronic health records create competitive advantages but raise privacy and interoperability challenges. Manufacturing capacity and the ability to control costs determine margin sustainability, and competition can compress prices for commonly used tests. Continued investment follows when clinical utility, predictable revenue and regulatory clarity align.